Business ❯ Corporate Governance

Executive Accountability

Financial Reporting Disclosure Obligations Investor Relations Securities Fraud Legal Compliance Financial Disclosure Shareholder Rights Fraudulent Practices Regulatory Compliance Fraud Allegations Securities Regulation Securities Regulations Securities Violations False Statements Financial Disclosures Risk Management Securities Disclosure Misrepresentation Public Relations IPO Regulations Securities Exchange Act Lawsuits Financial Mismanagement Legal Proceedings Shareholder Advocacy Market Competition Fraudulent Activities Management Practices Legal Risks Fraud Prevention Shareholder Actions Financial Management Financial Performance Public Statements Legal Liability Market Capitalization Material Disclosure High-Profile Executives Corporate Misconduct Resignations Fraud Employee Relations Financial Oversight Financial Misrepresentation Business Ethics Sarbanes-Oxley Act Market Performance Directors and Officers Marketing Strategy Investor Rights Misleading Statements Scandals Market Value Smartmatic Executives Bonuses and Penalties Environmental Responsibility Data Management Workplace Policies Financial Transparency Market Regulations Export Practices Workplace Misconduct Legal Consequences Chipotle Executives Regulatory Investigations Workplace Environment Legal Actions Bribery Scandal Crisis Management Company Performance Human Resources Industry Practices Competition Law Legal Penalties Leadership Succession and Compensation Penalties IPO Issues Oversight Responsibilities Legal Issues Sarepta Therapeutics, Inc. Employee Conduct Legal Violations Safety Regulations Legal Trials Securities Exchange Act Violations Legal Precedents IPO Process Deal Making Material Information Legal Investigations International Business Legal Settlements Market Access Restrictions Shareholder Lawsuits Financial Conduct Authority Crisis Response False Advertising Auditing Chief Executive Officer Stock Market Public Companies

Capricor Faces Multiple Securities Suits After FDA Flags Unapproved Changes to Trial Analysis

FDA classification of Capricor’s resubmission as a major amendment has moved the review deadline to Nov. 22, 2026.

Multiple Firms File Competing Class Actions Over Pentair’s Pool‑Channel Destocking

Investors Sue AppLovin Over Alleged Misleading Claims About AI Model Progress

Securities Suit Targets Capricor Over FDA Findings on Trial Analysis

Multiple Law Firms Court Wise Investors as Lead‑Plaintiff Deadline Nears

Capricor Faces Securities Class Action as FDA Extends Review of Duchenne Therapy

FTC Accuses Hims & Hers of Secretly Sharing Health Data as Stock Drops

Investors File Suit Against Rackspace Over AI Pivot and $150 Million Guidance Cut

Lawsuit Says Wix Misled Investors About AI Costs and Capabilities

Securities Suit Targets Cogent Over Alleged Illusory Wavelength Backlog

Securities Lawsuits Multiply Against Pentair After Pool-Channel Disclosure

UWM Hit With Securities Class Action Over Alleged Over‑Hedging

Investors File Securities Class Action Against PROCEPT BioRobotics

Multiple Firms Vie to Lead Erasca Securities Suits After April Disclosures

Class Action Targets Bloom Energy Over Alleged Hidden China Link in Scandium Supply

Class Action Targets Cogent Over Alleged Revenue Misstatements

Securities Class Action Filed Against Rackspace Over AI Pivot Claims

Securities Suits Target BitGo After IPO as Firms Race to Lead Litigation

Multiple Law Firms Seek Wix Shareholders for Securities Class Action Over AI Claims

Plaintiff Firms Press Investors Over PicS IPO Credit-Model Claims